TP-122A
AXP000232.1 · Phage therapy
- Platform
- phage cocktail (non-engineered)
- Originator
- Technophage
- Sponsor
- Technophage
Names
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- Pseudomonas aeruginosa bacteriophage
- Replication
- replicating
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06370598 | Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia | Unknown | Phase 1/2 | 2024-09 | 2025-05 | 15 | Pneumonia, Ventilator-Associated |
Recent changes
No changes recorded in its trials yet.
Notes
Anti-Pseudomonas aeruginosa phage product for ventilator-associated pneumonia; the registration calls it the component of the TP-122 cocktail and tests TP-122A itself (phase 1/2a NCT06370598). Separate program from TP-102, which is a different cocktail for a different indication.
How to cite
TP-122A (AXP000232.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000232.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.